No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014

Affiliations

• ¹ Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. Electronic address: lars.wallentin@ucr.uu.se.
• ² Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic Health Center, Cincinnati, OH, USA.
• ³ Cardiovascular Division, Brigham and Women's Hospital, Harvard Clinical Research Institute, Boston MA, USA.
• ⁴ Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
• ⁵ AstraZeneca Research and Development, Mölndal, Sweden.
• ⁶ Medical Department, Hospital Unit West, Herning/Holstbro, Denmark.
• ⁷ Medizinishe Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany.
• ⁸ Department of Medicine, Stanford University, Stanford, CA, USA.
• ⁹ Duke Clinical Research Institute, Duke University, Medical Center, Durham, NC, USA.
• ¹⁰ Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom.
• ¹¹ INSERM-Unité, 1148, Paris, France; Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK.